In reply
We wish to thank Lavoie and colleagues for their thoughtful letter. We agree with their suggestion that interventions in behavioral medicine be viewed analogously to phase 1, 2, and 3 clinical trials in drug development and thank them for pointing out the recommendations of the Office of Behavioral and Social Science Research.
Correspondence: Dr Berkowitz, Department of Medicine, University of California, San Francisco, 1545 Divisidero St, PO Box 0320, San Francisco, CA 94143 (Seth.Berkowitz@ucsf.edu).
Financial Disclosure: None reported.